Hologic Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for Hologic in a research note issued on Thursday. Leerink Swann analyst R. Newitter expects that the brokerage will earn $0.51 per share for the quarter. Leerink Swann has a “Outperform” rating and a $46.00 price target on the stock. Leerink Swann also issued estimates for Hologic’s Q2 2017 earnings at $0.53 EPS, Q3 2017 earnings at $0.55 EPS, Q4 2017 earnings at $0.56 EPS, FY2018 earnings at $2.37 EPS and FY2019 earnings at $2.66 EPS.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.03. The company had revenue of $717.40 million for the quarter, compared to analyst estimates of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 EPS.
A number of other brokerages have also recently weighed in on HOLX. RBC Capital Markets restated a “sector perform” rating and set a $39.00 price objective (up from $37.00) on shares of Hologic in a research note on Monday, August 1st. Piper Jaffray Cos. set a $44.00 price objective on shares of Hologic and gave the company a “hold” rating in a research note on Sunday, August 28th. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $42.00 to $44.00 in a research note on Friday, September 23rd. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price objective on the stock in a research note on Wednesday, September 28th. Finally, Royal Bank Of Canada lifted their target price on Hologic from $37.00 to $39.00 and gave the stock a “sector perform” rating in a report on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $42.71.
Hologic (NASDAQ:HOLX) opened at 38.88 on Monday. The firm has a 50-day moving average of $38.33 and a 200-day moving average of $36.10. The stock has a market capitalization of $10.79 billion, a price-to-earnings ratio of 42.87 and a beta of 1.00. Hologic has a 12-month low of $31.84 and a 12-month high of $41.66.
Large investors have recently made changes to their positions in the company. Cleararc Capital Inc. acquired a new stake in shares of Hologic during the first quarter worth approximately $213,000. Quadrature Capital Ltd acquired a new stake in shares of Hologic during the first quarter worth approximately $2,704,000. UBS Asset Management Americas Inc. raised its stake in shares of Hologic by 1.2% in the first quarter. UBS Asset Management Americas Inc. now owns 637,813 shares of the company’s stock worth $22,006,000 after buying an additional 7,810 shares during the last quarter. UBS Group AG raised its stake in shares of Hologic by 5.8% in the first quarter. UBS Group AG now owns 794,751 shares of the company’s stock worth $27,419,000 after buying an additional 43,652 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Hologic by 26.4% in the first quarter. State Street Corp now owns 10,295,836 shares of the company’s stock worth $355,210,000 after buying an additional 2,150,544 shares during the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.
In other Hologic news, Director Nancy Leaming sold 6,221 shares of the firm’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $36.04, for a total transaction of $224,204.84. Following the completion of the sale, the director now directly owns 55,053 shares in the company, valued at approximately $1,984,110.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.84% of the stock is owned by corporate insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.